Table 3 Cost-effectiveness results for cohort of 5000 women (costs are in USD)
Strategy | Total costs | Incremental costs | Total infections | Infections averted | ICERa |
|---|---|---|---|---|---|
Vaccine only | $21,673.15 | base case | 64 | base case | base case |
HBIG after confirmatory test | $40,553.86 | -- | 41 | -- | extended dominance |
HBIG after RDT | $47,477.10 | $25,803.95 | 28 | 36 | $716.78 |